Furthermore, while ESR1 can initially upregulate AGR2 expression, breast cancer cells that achieve tamoxifen resistance no longer require ESR1 for AGR2 expression, likely due to an alteration in the activity of the transcription factor FOXA1 [19]. This evidence concerns the gene FOXA1 and breast carcinoma.